You are here: Industry Insights > NSCLC

News List

AZ’ lung cancer drug Tagrisso backed for first-line use pharmatimes
July 12, 2018
European regulatory advisors are supporting approval of AstraZeneca’s lung cancer drug Tagrisso in the first-line setting.
Three cancer treatments approved for use on NHS Scotland pharmatimes
July 11, 2018
Three treatments have been approved for NHS funding in Scotland, bringing new options for gastroenteropancreatic tumours, lung and kidney cancers, but patients with multiple sclerosis will be unable to access Roche’s Ocrevus following a rejection by the S
EU approves first-line use of AZ’ Tagrisso in lung cancer pharmatimes
July 10, 2018
AstraZeneca’s Tagrisso has been given a green light in Europe for first-line use to treat EGFR-mutated non-small cell lung cancer (NSCLC), offering a new line of attack at this stage of the disease.
First-line use of Roche’s Tecentriq given priority review pharmatimes
July 09, 2018
US regulators are undertaking a priority review of Roche unit Genentech’s PD-L1 inhibitor Tecentriq, in combination with Avastin and standard chemotherapy for some patients with lung cancer.
ASCO: Pfizer’s dacomitinib bests Iressa in NSCLC overall survival showdown fiercebiotech
June 11, 2018
A phase 3 trial has linked Pfizer’s dacomitinib to better overall survival (OS) than Iressa in nonsmall cell lung cancer (NSCLC).
MSD’s Keytruda takes lead in squamous NSCLC trials pharmatimes
June 06, 2018
MSD’s Keytruda has shown a greater benefit than Roche’s Tecentriq in separate (and incomparable) clinical trials exploring the effectiveness of the anti-PD-1 therapies in treatment-naiive patients with squamous non-small cell lung cancer.
FDA grants Keytruda priority review pharmatimes
May 02, 2018
The FDA has accepted for review Merck & Co's anti-PD-1 therapy Keytruda in combination with Eli Lilly's Alimta (pemetrexed) and platinum chemotherapy ...
MSD’s Keytruda bags another trial success in NSCLC pharmatimes
April 11, 2018
MSD’s Keytruda has significantly increased overall survival in patients with lung cancer expressing any level of PD-L1 when used as monotherapy in the first-line setting, potentially significantly increasing the drug’s treatment scope.
Opdivo May Be the First Marketed in China, Chinese Pharmaceutical Enterprises are Catching up Fast! Zhixing
January 17, 2018
Anti-PD-1 monoclonal antibodies are very popular with pharmaceutical enterprises, however, it is hard to find such monoclonal antibody in China.
Moffitt scientists discover new applications for Novartis's Zykadia pharmafile
October 12, 2017
Researchers at Moffitt screened 240 FDA-approved treatments as well as those currently in development to identify potential alternative uses.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 20 21 Next page